Page 709 - Withrow and MacEwen's Small Animal Clinical Oncology, 6th Edition

CHAPTER 32 Ocular Tumors 687

83. Hendrix DV, Gelatt KN, Smith PJ, et al.: Ophthalmic disease as 102. Miller PE, Turek MM, Forrest LJ, et al.: Ocular sparing using
the presenting complaint in five dogs with multiple myeloma, J Am intensity modulated radiation therapy (IMRT) in a canine model
Anim Hosp Assoc 34:121–128, 1998. of spontaneous sinonasal cancer: proof of principle of conformal
VetBooks.ir 84. Attali-Soussay K, Jegou JP, Clerc B: Retrobulbar tumors in dogs 103. Lawrence JA, Forrest LJ, Turek MM, et al.: Proof of principle of
avoidance, Invest Ophthalmol Vis Sci 46:5408, 2005.
and cats: 25 cases, Vet Ophthalmol 4:19–27, 2001.
85. Mauldin EA, Deehr AJ, Hertzke D, et al.: Canine orbital menin-
giomas: a review of 22 cases, Vet Ophthalmol 3:11–16, 2000. ocular sparing in dogs with sinonasal tumors treated with intensity-
modulated radiation therapy, Vet Radiol Ultrasound 51:561–570,
86. Gilger BC, McLaughlin SA, Whitley RD, et al.: Orbital neoplasms 2010.
in cats: 21 cases (1974-1990), J Am Vet Med Assoc 201:1083–1086, 104. Imperia PS, Lazarus HM, Lass JH: Ocular complications of sys-
1992. temic cancer chemotherapy, Surg Ophthalmol 34:209–230, 1989.
87. Kern TJ: Orbital neoplasia in 23 dogs, J Am Vet Med Assoc 186:489– 105. Martin PL, Miller PE, Mata M, et al.: Ocular inflammation in
491, 1985. cynomolgus macaques following intravenous administration of a
88. Braund KG, Ribas JL: Central nervous system meningiomas, Com- human monoclonal antibody, J Toxicol 28:5–16, 2009.
pend Contin Educ Pract Vet 8:241–248, 1986. 106. Eaton JS, Miller PE, Mannis MJ, et al.: Ocular adverse events asso-
89. Headrick JK, Bentley E, Dubielzig RR: Canine lobular orbital ade- ciated with antibody drug conjugates in human clinical trials, J
noma: a report of 15 cases with distinctive features, Vet Ophthalmol Ocular PharmTher 31:589–604, 2015.
7:47–51, 2004. 107. Kheir WJ, Sniegowski MC, El-Sawy T, et al.: Ophthalmic compli-
90. Dugan SJ, Schwarz PD, Roberts SM, et al.: Primary optic nerve cations of targeted cancer therapy and recently recognized ophthal-
meningioma and pulmonary metastasis in a dog, J Am Anim Hosp mic complications of traditional chemotherapy, Surv Ophthalmol
Assoc 29:11–16, 1993. 59:493–502, 2014.
91. Spiess BM, Wilcock BP: Glioma of the optic nerve with intraocular 108. Chattopahdyay C, Kim DW, Gombos D, et al.: Uveal melanoma:
and intracranial involvement in a dog, J Comp Pathol 97:79–84, from diagnosis to treatment and the science in between, Cancer
1987. 122:2299–2312, 2016.
92. Naranjo C, Schobert C, Dubielzig RR: Canine ocular gliomas: a 109. Diener-West M, Earle JD, Fine SL, et al.: The COMS random-
retrospective study, Vet Ophthalmol 11:356–362, 2008. ized trial of iodine 125 brachytherapy for choroidal melanoma, III:
93. Scott EM, Teixeira LBC, Flanders DJ, et al.: Canine orbital rhab- Initial mortality findings, COMS Report No. 18, Arch Ophthalmol
domyosarcoma: a report of 18 cases, Vet Ophthalmol 19:130–137, 119:969–982, 2001.
2016. 110. Syed NA, Nork TM, Poulsen GL, et al.: Retinoblastoma in a dog,
94. Slatter DH, Abdelbaki Y: Lateral orbitotomy by zygomatic arch Arch Ophthalmol 115:758–763, 1997.
resection in the dog, J Am Vet Med Assoc 175:1179–1182, 1979. 111. Shields CL, Meadows AT, Leahey AM, et al.: Continuing chal-
95. Gilger BC, Whitely RD, McLaughlin SA: Modified lateral orbi- lenges in the management of retinoblastoma with chemotherapy,
totomy for removal of orbital neoplasms in two dogs, Vet Surg Retina 24:849–862, 2004.
23:53–58, 1994. 112. Guy J, Aptiauri N: Treatment of paraneoplastic visual loss with
96. O’Brien MG, Withrow SJ, Straw RC, et al.: Total and partial orbi- intravenous immunoglobulin: report of 3 cases, Arch Ophthalmol
tectomy for the treatment of periorbital tumors in 24 dogs and 6 117:471–477, 1999.
cats: a retrospective study, Vet Surg 25:471–479, 1996. 113. Subramanian L, Polan AS: Cancer-related diseases of the eye: the
97. Håkansson NW, Håkansson BW: Transfrontal orbitotomy in the role of calcium-binding proteins, Biochem Biophys Res Commun
dog: an adaptable three-step approach to the orbit, Vet Ophthalmol 322:1153–1165, 2004.
13:377–383, 2010. 114. Ohgura H, Yokoi Y, Ohguro I, et al.: Clinical and immuno-
98. Bartoe JT, Brightman AH, Davidson HJ: Modified lateral orbi- logic aspects of cancer-associated retinopathy, Am J Ophthalmol
totomy for vision-sparing excision of a zygomatic mucocele in a 137:1117–1119, 2004.
dog, Vet Ophthalmol 10:127–131, 2007. 115. Gilmour MA, Cardenas MR, Blaik MA, et al.: Evaluation of a
99. Wallin-Håkansson N, Berggren K: Orbital reconstruction in the comparative pathogenesis between cancer-associated retinopathy
dog, cat and horse, Vet Ophthalmol 20:316–328, 2017. in humans and sudden acquired retinal degeneration syndrome in
100. Adams WM, Miller PE, Vail DM, et al.: An accelerated tech- dogs via diagnostic imaging and western blot analysis, Am J Vet Res
nique for irradiation of malignant canine nasal and paranasal sinus 67:877–881, 2006.
tumors, Vet Radiol Ultrasound 5:475–481, 1998.
101. Roberts SM, Lavach JD, Severin GA, et al.: Ophthalmic complica-
tions following megavoltage irradiation of the nasal and paranasal
cavities in dogs, J Am Vet Med Assoc 190:43–47, 1987.